LORICRIN and Alzheimer disease: Epidermal barrier impairment has a prominent role in the pathogenesis of AD, which is attributed to filaggrin null mutations; involucrin, loricrin, and lipid (mainly ceramide) abnormalities; and interference between epidermal barrier cells and immunological pathways that entail the Th2 differentiation of lymphocytes in AD [2].